Familial orthostatic tachycardia

Current Opinion in Cardiology

Volumn 21, Issue 3, 2006, Pages 173-179

  Keller, Nancy R ^a   Robertson, David ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autonomic dysfunction; Genetic testing; Orthostatic tachycardia; Partial dysautonomia

Indexed keywords

ADRENERGIC RECEPTOR; DOPAMINE BETA MONOOXYGENASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; NICOTINIC RECEPTOR; NORADRENALIN TRANSPORTER; TENASCIN;

AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NEUROPATHY; BLOOD VESSEL PERMEABILITY; DISEASE ASSOCIATION; DNA FLANKING REGION; DYSAUTONOMIA; EHLERS DANLOS SYNDROME; FAMILIAL DISEASE; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; HYPERSENSITIVITY; INCIDENCE; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; TACHYCARDIA; VASOCONSTRICTION;

AUTONOMIC NERVOUS SYSTEM DISEASES; CAPILLARY PERMEABILITY; DOPAMINE BETA-HYDROXYLASE; FEMALE; HUMANS; MUTATION; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; POSTURE; RECEPTORS, NICOTINIC; SYNDROME; TACHYCARDIA; VASOCONSTRICTION;

EID: 33748196481     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000221577.41125.c8     Document Type: Review

References (79)

1. Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci 1999; 317:75-77.
2. Raj SR, Biaggioni I, Robenson D. Current concepts: the postural tachycardia syndrome. New Engl J Med 2006; in press.
3. Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 1997; 96:575-580.
4. Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. New Engl J Med 2000; 342:541-549.
5. Ivancsits S, Heider A, Rudiger H, et al. Orthostatic intolerance is not necessarily related to a specific mutation (Ala457Pro) in the human norepinephrine transporter gene. Am J Med Sci 2003; 325:63-65.
6. Ali YS, Daamen N, Jacob G, et al. Orthostatic intolerance: a disorder of young women. Obstet Gyn Survey 2000; 55:251-259.
7. Christou DD, Jones PP, Jordan J, et al. Women have lower tonic autonomic support of arterial blood pressure and less effective baroreflex buffering than men. Circulation 2005; 111:494-498. Healthy premenopausal women showed lower baseline systolic BP and plasma catecholamines, and tonic autonomic nervous system support of BP was 50-65% lower in women.
8. Evans JM, Ziegler MG, Patwardhan AR, et al. Gender differences in autonomic cardiovascular regulation: spectral, hormonal, and hemodynamic indexes. J Appl Physiol 2001; 91:2611-2618.
9. Cunningham DS, Brodnik RM, Rayl DL, et al. Suboptimal progesterone production in pathologic pregnancies. J Reprod Med 1993; 38:301-305.
10. Ramirez N. Pathology of the endometrium. In: Diamond M, Osteen K, editors. Endometrium and endometriosis. Oxford: Blackwell Science, Inc.; 1997. pp. 7-19.
11. Hahn MK, Mazei-Robison MS, Blakely RD. Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharm 2005; 68:457-466. Naturally occurring single-nucleotide polymorphisms in cardiovascular phenotypes were shown to affect protein expression through aberrant glycosylation and altered surface expression. Expression with native protein demonstrated a dominant-negative impact on hNET expression and cell surface targeting.
12. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 2003; 23:4470-4478.
13. Robertson D, Goldberg MR, Hollister AS, et al. Isolated failure of autonomic noradrenergic neurotransmission: evidence for impaired beta-hydroxylation of dopamine. N Engl J Med 1986; 314:1494-1497.
14. Man in't Veld AJ, Boomsma F, Moleman P, et al. Congenital dopamine-beta-hydroxylase deficiency. Lancet 1987; 1:183-187.
15. Cho S, Kim CH, Cubells JF, et al. Variations in the dopamine β-hydroxylase gene are not associated with the autonomic disorders, pure autonomic failure, or multiple system atrophy. Am J Med Genet 2003; 120A:234-236.
16. Kim CH, Zabetian CP, Cubells JF, et al. Mutations in the dopamine-β-hydroxylase gene associated with human norepinephrine deficiency. Am J Med Genet 2002; 108:140-147.
17. Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci 1999; 317:88-101.
18. Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. New Engl J Med 2000; 343:1008-1014.
19. Bonyhay I, Freeman R. Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation 2004; 110:3193-3198.
20. Stewart JM. Chronic orthostatic intolerance and the postural tachycardia syndrome. J Pediatr 2004; 145:725-773.
21. Tani H, Singer W, McPhee BR, et al. Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS). Auton Neurosci 2000; 86:107-113.
22. Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847-855.
23. Sandroni P, Vernino S, Klein CM, et al. Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 2004; 61:44-48.
24. McGehee DS. Molecular diversity of neuronal nicotinic acetylcholine receptors. Ann NY Acad Sci 1999; 868:565-577.
25. Xu W, Gelber S, Orr-Urtreger A, et al. Megacystis, mydriasis, and ion channel defect in mice lacking the α3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 1999; 96:5746-5751.
26. Wang N, Orr-Urtreger A, Chapman J, et al. Autonomic function in mice lacking α5 neuronal nicotinic acetylcholine receptor subunit. J Physiol 2002; 542:347-354.
27. Wang N, Orr-Urtreger A, Chapman J, et al. Deficiency of nicotinic acetylcholine receptor β4 subunit causes autonomic cardiac and intestinal dysfunction. Mol Pharmacol 2003; 63:574-580.
28. Duga S, Solda' G, Asselta R, et al. Characterization of the genomic structure of the human neuronal nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster and identification of novel intragenic polymorphisms. J Hum Genet 2001; 46:640-648.
29. Liang Y, Salas R, Marubio L, et al. Functional polymorphisms in the human β4 subunit of nicotinic acetylcholine receptors. Neurogenetics 2004; 6:37-44.
30. Salas R, Pieri F, Fung B, et al. Altered anxiety-related responses in mutant mice lacking the β4 subunit of the nicotinic receptor. J Neurosci 2003; 23:6255-6263.
31. Mahata SK, Mahata M, Wen G, et al. The catecholamine release-inhibitory "catestatin" fragment of chromogranin A: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 2004; 66:1180-1191.
32. Nannipieri M, Posadas R, Williams K, et al. Association between polymorphisms of the atrial natriuretic peptide gene and proteinuria: a population-based study. Diabetologia 2003; 46:429-432.
33. Roussel R, Tregouet DA, Hadjadj S, et al. Investigation of the human ANP gene in type 1 diabetic nephropathy: case-control and follow-up studies. Diabetes 2004; 53:1394-1398.
34. Rubattu S, Stanzione R, Di Angelantonio E, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004; 35:814-818.
35. Sabrane K, Kruse MN, Fabritz L, et al. The hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005; 115:1666-1674. Selective endothelial inactivation of the guanylyl cyclase-A receptor for ANP in mice showed that the vasorelaxing properties of ANP were preserved; however, knockouts had chronic hypertension, hypervolemia, and global cardiac hypertrophy. Cardiovascular measurements with and without dietary salt restriction demonstrated no effect.
36. Schubert W, Frank PG, Woodman SE, et al. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 2002; 277:40091-40098.
37. Garland EM, Winker R, Williams SM, et al. Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension 2005; 46:1103-1110. Allelic frequencies of 136 POTS patients from Nashville, Tennessee, USA, and Vienna, Austria, were compared with those of 191 healthy subjects and correlated with orthostatic testing with BP, heart rate, and catecholamine measurements in the supine and upright positions.
38. •].
39. Hungerford JE, Little CD. Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. J Vasc Res 1999; 36:2-27.
40. Nissen R, Cardinale GJ, Udenfriend S. Increased turnover of arterial collagen in hypertensive rats. Proc Natl Acad Sci USA 1978; 75:451-456.
41. Bou-Gharios G, Ponticos M, Rajkumar V, et al. Extra-cellular matrix in vascular networks. Cell Prolif 2004; 37:207-220.
42. Schroen D, Brinckerhoff C. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Expr 1996; 6:197-207.
43. Keller N, Sierra-Rivera E, Eisenberg E, et al. Progesterone prevents IL-1a stimulation of MMP-3 in human endometrial stromal cells. J Clin Endocrinol Metab 2000; 85:1611-1619.
44. Tayebjee MH, Tan KT, MacFadyen RJ, et al. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Int Med 2005; 257:110-116. Study of 36 patients with intermittent claudication and 43 with critical ischemia by angiography. Levels of MMP-9 and TIMP-1 (tissue inhibitor of metalloproteinases-1) were higher in both patient groups compared with controls, and levels in the ischemic group were significantly higher than in those with claudication.
45. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2005 [Epub ahead of print]. Polymorphisms in the MMP-3 and other MMP genes are described, and associations with coronary stenosis, myocardial infarction, coronary artery calcification and restenosis, carotid atherosclerosis, stroke, arterial stiffness, and BP are detailed, in this excellent review.
46. Grahame R. Joint hypermobility and genetic collagen disorders: are they related? Arch Dis Child 1999; 80:188-191.
47. Brown CM, Stemper B, Welsch G, et al. Orthostatic challenge reveals impaired vascular resistance control, but normal venous pooling and capillary filtration in familial dysautonomia. Clin Sci 2003; 104:163-169.
48. Hakim AJ, MacGregor AJ, Spector TD. Joint hypermobility in the general population is common and strongly genetically determined: results of a study of female twins from a national sample. Arthritis Rheum 2003; 48 (Suppl. 9):S682.
49. Gazit Y, Nahir AM, Grahame R, et al. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115:33-40.
50. Rowe PC, Barron DF, Calkins H, et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135:494-499.
51. Armstrong DJ. Non-musculoskeletal symptoms in joint hypermobility syndrome. Indirect evidence for autonomic dysfunction? Rheumatology 2004; 43:1194-1202.
52. Zweers MC, Hakim AJ, Grahame R, et al. Joint hypermobility syndromes: the pathophysiologic role of tenascin-X gene defects. Arthritis Rheum 2004; 50:2742-2749.
53. Beilby JP, Chapman CM, Palmer LJ, et al. Stromelysin-1 (MMP-3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population. J Hypertens 2005; 23:537-542.
54. Medley TL, Kingwell BA, Gatzka CD, et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92:1254-1261.
55. Harendza S, Lovett DH, Panzer U, et al. Linked common polymorphisms in the genatinase A promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003; 278:20490-20499.
56. Mawrin C, Brunn A, Rocken C, et al. Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol 2003; 105:365-372.
57. Johnson EO, Zoubos AB, Soucacos P. Regeneration and repair of peripheral nerves. Injury 2005; 36 (Suppl. 4):S24-S29. The cellular and molecular biology of sensory and motor peripheral nerve injury and repair is detailed, as well as natural and synthetic tubular nerve guidance channels. Without Schwann cells, basal lamina, growth factors and perineurial continuity, however, successful regrowth following injury is unlikely.
58. Hoitsma E, Reulen JPH, de Baets M, et al. Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004; 227:119-130.
59. Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365:1259-1270. Autonomic neuropathies as the result of diabetes, amyloid deposition, autoimmunity, paraneoplastic syndrome, and neurotoxins are described in detail, as are several familial autonomic neuropathies. Autonomic function and laboratory testing are discussed to aid in differential diagnosis.
60. Hoke A, Ho T, Crawford TO, et al. Glial cell line-derived neurotrophic factor alters axon Schwann cell units and promotes myelination in unmyelinated nerve fibers. J Neurosci 2003; 23:561-567.
61. Koenig HL, Gong WH, Pelissier P. Role of progesterone in peripheral nerve repair. Rev Reprod 2000; 5:189-199.
62. Straub RH, Harle P. Sympathetic neurotransmitters in joint inflammation. Rheum Dis Clin N Am 2005; 31:43-59. An excellent review detailing the loss of sympathetic nerve fibers in rheumatoid arthritis and a rat model of arthritis. There is thorough illustration and explanation of the norepinephrine concentration gradient in the inflamed joint and the β- to α-adrenergic shift during disease progression that perpetuates cytokine release and tissue degradation.
63. Miller LE, Justen HP, Scholmerich J, et al. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000; 14:2097-2107.
64. Wahle M, Krause A, Ulrichs T, et al. Disease activity related catecholamine response of lymphocytes from patients with rheumatoid arthritis. Ann NY Acad Sci 1999; 876:287-296.
65. Osteen KG, Keller NR, Feltus FA, et al. Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium. Gyn Obstet Invest 1999; 48 (Suppl. 1):2-13.
66. Huck B, Steck T, Habersack M, et al. Pregnancy associated hormones modulate the cytokine production but not the phenotype of PBMC-derived human dendritic cells. Eur J Obstet Gynecol Reprod Biol 2005; 122:85-94. Treatment of immature and mature dendritic cells with estradiol or progesterone stimulated interleukin-10 production, while progesterone in combination with either estradiol or β-human chorionic gonadotropin inhibited interleukin-18 production by mature cells. A thorough evaluation of surface marker expression and cytokine profiles in response to hormone treatment is presented.
67. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411.
68. C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-1142.
69. Stein CM, Lang CC, Xie HG, Wood AJ. Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics 2001; 11:95-110.
70. Timmermann B, Mo R, Luft FC, et al. Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney Int 1998; 53:1455-1460.
71. Iaccarino G, Lanni F, Cipolletta E, et al. The Glu27 allele of the beta2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J Hypertens 2004; 22:2117-2122.
72. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 1996; 93:10483-10488.
73. Brodde O-E, Buscher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001; 103:1048-1050.
74. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402:181-184.
75. 2C adrenergic receptors: diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci USA 2004; 101:13020-13025.
76. 2C- adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275:23059-23064.
77. 2-adrenoceptor antagonist.
78. Finley JC, O'Leary M, Wester D, et al. A genetic polymorphism of the α2-adrenergic receptor increases autonomic responses to stress. J Appl Physiol 2004; 96:2231-2239.
79. Wang Q. Molecular genetics of coronary artery disease. Curr Opin Cardiol 2005; 20:182-188.